Investigators are evaluating whether eryaspase (Graspa), an L-asparaginase-based therapy that triggers tumor cell death, can extend survival for patients with pancreatic cancer. Patients with advanced pancreatic adenocarcinoma have few effective treatment options outside of a clinical trial or palliative care,1 and this could solve an unmet medical need.
“Patients [with pancreatic cancer] who progress after first-line therapy only really have 1 option, and that’s nanoliposomal irinotecan (Onivyde),” said Manuel Hidalgo, MD, PhD Read more . . .